<table id="t7" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 7:          Drug Interactions: Pharmacokinetic Parameters for Simeprevir in the Presence of Co-administered Drugs</caption>
<col align="left" valign="top" width="20%"></col>
<col align="center" valign="top" width="15%"></col>
<col align="center" valign="top" width="15%"></col>
<col align="center" valign="top" width="5%"></col>
<col align="center" valign="top" width="6%"></col>
<col align="center" valign="top" width="13%"></col>
<col align="center" valign="top" width="13%"></col>
<col align="center" valign="top" width="13%"></col>
<thead>
<tr stylecode="Botrule">
<th rowspan="2" stylecode="Lrule Rrule">Co-administered Drug</th>
<th colspan="2" stylecode="Rrule">Dose (mg) and Schedule</th>
<th rowspan="2" stylecode="Rrule">N</th>
<th rowspan="2" stylecode="Rrule">Effect on PK<footnote>The direction of the arrow (↑ = increase, ↓ = decrease, ↔ = no change) indicates the direction of the change in PK (i.e., AUC).</footnote>
</th>
<th colspan="3" stylecode="Rrule">LS Mean Ratio (90% CI) of <content stylecode="underline">Simeprevir </content>PK Parameters<br/>with/without Drug</th>
</tr>
<tr>
<th align="center" stylecode="Rrule">Drug</th>
<th stylecode="Rrule">Simeprevir</th>
<th stylecode="Rrule">C<sub>max</sub>
</th>
<th stylecode="Rrule">AUC</th>
<th stylecode="Rrule">C<sub>min</sub>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="8">CI = Confidence Interval; N = number of subjects with data; NA = not available; PK = pharmacokinetics; LS = least square; q.d. = once daily; b.i.d. = twice daily; t.i.d. = three times a day</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cyclosporine<footnote id="ft7.1">Comparison based on historic controls. Interim data from a Phase 2 trial in combination with an investigational drug and RBV in HCV-infected post-liver transplant patients.</footnote>
</td>
<td stylecode="Rrule">individualized dose<footnote id="ft7.2">Individualized dose at the discretion of the physician, according to local clinical practice.</footnote>
</td>
<td stylecode="Rrule">150 mg q.d. for 14 days</td>
<td stylecode="Rrule">9</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">4.74<br/>(3.12–7.18)</td>
<td stylecode="Rrule">5.81<br/>(3.56–9.48)</td>
<td stylecode="Rrule">NA</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Erythromycin</td>
<td stylecode="Rrule">500 mg t.i.d.<br/>for 7 days</td>
<td stylecode="Rrule">150 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">24</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">4.53<br/>(3.91–5.25)</td>
<td stylecode="Rrule">7.47<br/>(6.41–8.70)</td>
<td stylecode="Rrule">12.74<br/>(10.19–15.93)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Escitalopram</td>
<td stylecode="Rrule">10 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">150 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">18</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.80<br/>(0.71–0.89)</td>
<td stylecode="Rrule">0.75<br/>(0.68–0.83)</td>
<td stylecode="Rrule">0.68<br/>(0.59–0.79)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifampin</td>
<td stylecode="Rrule">600 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">200 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">18</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">1.31<br/>(1.03–1.66)</td>
<td stylecode="Rrule">0.52<br/>(0.41–0.67)</td>
<td stylecode="Rrule">0.08<br/>(0.06–0.11)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tacrolimus<footnoteref idref="ft7.1"></footnoteref>
</td>
<td stylecode="Rrule">individualized dose<footnoteref idref="ft7.2"></footnoteref>
</td>
<td stylecode="Rrule">150 mg q.d. for 14 days</td>
<td stylecode="Rrule">11</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.79<br/>(1.22–2.62)</td>
<td stylecode="Rrule">1.85<br/>(1.18–2.91)</td>
<td stylecode="Rrule">NA</td>
</tr>
<tr stylecode="Botrule">
<td colspan="8" stylecode="Lrule Rrule">
<content stylecode="bold">Anti-HCV Drug</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sofosbuvir<footnote>Comparison based on historic controls. The interaction between simeprevir and sofosbuvir was evaluated in a pharmacokinetic substudy within a Phase 2 trial.</footnote>
</td>
<td stylecode="Rrule">400 mg q.d.</td>
<td stylecode="Rrule">150 mg q.d.</td>
<td stylecode="Rrule">21</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">0.96<br/>(0.71–1.30)</td>
<td stylecode="Rrule">0.94<br/>(0.67–1.33)</td>
<td stylecode="Rrule">NA</td>
</tr>
<tr stylecode="Botrule">
<td colspan="8" stylecode="Lrule Rrule">
<content stylecode="bold">Anti-HIV Drugs</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Darunavir/Ritonavir<footnote>The dose of OLYSIO in this interaction study was 50 mg when co-administered in combination with darunavir/ritonavir compared to 150 mg once daily in the OLYSIO alone treatment group.</footnote>
</td>
<td stylecode="Rrule">800/100 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">50 mg and 150 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">25</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.79<br/>(1.55–2.06)</td>
<td stylecode="Rrule">2.59<br/>(2.15–3.11)</td>
<td stylecode="Rrule">4.58<br/>(3.54–5.92)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Efavirenz</td>
<td stylecode="Rrule">600 mg q.d.<br/>for 14 days</td>
<td stylecode="Rrule">150 mg q.d.<br/>for 14 days</td>
<td stylecode="Rrule">23</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.49<br/>(0.44–0.54)</td>
<td stylecode="Rrule">0.29<br/>(0.26–0.33)</td>
<td stylecode="Rrule">0.09<br/>(0.08–0.12)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Raltegravir</td>
<td stylecode="Rrule">400 mg b.i.d.<br/>for 7 days</td>
<td stylecode="Rrule">150 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">24</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">0.93<br/>(0.85–1.02)</td>
<td stylecode="Rrule">0.89<br/>(0.81–0.98)</td>
<td stylecode="Rrule">0.86<br/>(0.75–0.98)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rilpivirine</td>
<td stylecode="Rrule">25 mg q.d.<br/>for 11 days</td>
<td stylecode="Rrule">150 mg q.d.<br/>for 11 days</td>
<td stylecode="Rrule">21</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">1.10<br/>(0.97–1.26)</td>
<td stylecode="Rrule">1.06<br/>(0.94–1.19)</td>
<td stylecode="Rrule">0.96<br/>(0.83–1.11)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ritonavir</td>
<td stylecode="Rrule">100 mg b.i.d.<br/>for 15 days</td>
<td stylecode="Rrule">200 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">12</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">4.70<br/>(3.84–5.76)</td>
<td stylecode="Rrule">7.18<br/>(5.63–9.15)</td>
<td stylecode="Rrule">14.35<br/>(10.29–20.01)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Tenofovir disoproxil fumarate</td>
<td stylecode="Rrule">300 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">150 mg q.d.<br/>for 7 days</td>
<td stylecode="Rrule">24</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.85<br/>(0.73–0.99)</td>
<td stylecode="Rrule">0.86<br/>(0.76–0.98)</td>
<td stylecode="Rrule">0.93<br/>(0.78–1.11)</td>
</tr>
</tbody>
</table>